By Denny Jacob
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
The drug maker logged net income of $2.76 billion, or $3.06 a share, up from $2.24 billion, or $2.48 a share, in the prior-year period.
Stripping out certain one-time items, earnings came in at $3.34 a share. Analysts polled by FactSet expected $3.26 a share.
Revenue soared 45% to $12.73 billion from $8.77 billion. Analysts polled by FactSet expected $12.67 billion.
Revenue in the U.S. came in at $8.49 billion off higher volume driven by Zepbound and Mounjaro, though partially offset by lower realized prices. Revenue outside the U.S. totaled $4.24 billion, driven by higher volume primarily tied to Mounjaro and, to a lesser extent, Jardiance.
Eli Lilly reduced its adjusted earnings per-share outlook for the year due to a recognized acquired in-process research and development charge of $1.57 billion recognized in the quarter. The company now expects adjusted EPS between $20.78 and $22.28 for the year, down from a prior adjusted EPS forecast between $22.50 and $24.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 01, 2025 07:09 ET (11:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。